Ansiedad y depresión en hombres con cáncer de próstata en función del tipo de tratamiento y su relación con la calidad de vida y la información recibida

  1. Natalia Oraá-Tabernero 1
  2. Juan Antonio Cruzado 2
  1. 1 Centro de Psico-Oncología. Logroño (Spain)
  2. 2 Universidad Complutense de Madrid. Facultad de Psicología (Spain)
Journal:
Psicooncología: investigación y clínica biopsicosocial en oncología

ISSN: 1696-7240

Year of publication: 2019

Volume: 16

Issue: 2

Pages: 329-344

Type: Article

DOI: 10.5209/PSIC.65594 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Psicooncología: investigación y clínica biopsicosocial en oncología

Abstract

Objective: To know the level of anxiety and depression that patients with prostate cancer have based on sociodemographic variables (age, level of studies, employment status or having a partner) and clinical variables (risk group, type of treatment or survival phase), and how the emotional state can vary depending on the quality of life and the information received. Method: 176 men were randomly selected, between 2015-2016, who had received local, hormonal or combined treatments. An interview was conducted and the BAI, BDI-II, EORTC QLQ-C30, EORTC QLQ-PR25 and EORTC QLQ-INFO25 questionnaires were administered. Results: BAI and BDI-II inventory scores are low, depression symptoms are higher and appear more frequently. There are no significant differences depending on the sociodemographic variables or clinical variables such as the risk group or the survival phase. However, men who receive hormonal treatments suffer more anxiety and depression than those who receive local treatments. In addition, men who have worse quality of life and / or received worse information have more symptoms of anxiety and depression. Conclusions: In general, our men do not present anxiety or clinical depression. Special care should be given to men who receive hormonal treatments, those who suffer adverse effects from the treatments or have a worse quality of life. And in all cases, it is necessary to improve communication from the moment of diagnosis, among other things, because the properly informed man has a better emotional state

€ View funding

Funding information

Nuestros resultados, tanto de la muestra global del Inventario de Ansiedad de Beck (BAI) y del Inventario de Depresión de Beck-II (BDI-II), indican que las puntuaciones en ambos cuestionarios son bajas y la media global no indica ansiedad o depresión clínica, siendo la sintomatología depresiva más elevada y apareciendo con más frecuencia que la ansiedad.

Funders

Bibliographic References

  • Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993; 85: 365-76. doi: 10.1093/jnci/85.5.365.
  • Arraras JI, Arias F, Tejedor M, Pruja E, Marcos M, Martínez E, et al. The EORTC QLQ-C30 (version 3.0) Quality of Life questionnaire: validation study for Spain with head and neck cancer patients. Psychooncology 2002; 11: 249-56. doi: 10.1002/pon.555.
  • Arraras JI, Greimel E, Sezer O, Chie W-C, Bergenmar M, Costantini A, et al. An international validation study of the EORTC QLQ-INFO25 questionnaire: an instrument to assess the information given to cancer patients. Eur J Cancer 1990. 2010; 46: 2726-38. doi: 10.1016/j.ejca.2010.06.118.
  • Arraras JI, Manterola A, Hernández B, Arias de la Vega F, Martínez M, Vila M, et al. The EORTC information questionnaire, EORTC QLQ-INFO25. Validation study for Spanish patients. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. Junio de 2011; 13: 401-10. doi: 10.1007/s12094-011-0674-1.
  • Arraras JI, Villafranca E, Vega FA de la, Romero P, Rico M, Vila M, et al. The EORTC Quality of Life Questionnaire for patients with prostate cancer: EORTC QLQ-PR25. Validation study for Spanish patients. Clin Transl Oncol 2009; 11: 160-4. doi: 10.1007/S12094-009-0332-z.
  • Balderson N, Towell T. The prevalence and predictors of psychological distress in men with prostate cancer who are seeking support. Br J Health Psychol 2003; 8: 125-34. doi: 10.1348/135910703321649114.
  • Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56: 893-7. doi: 10.1.37//0022-006x.56.6.893.
  • Beck AT, Steer RA, Brown GK. Manual. BDI-II. Inventario de Depresión de Beck-II (Adaptación española: Sanz J, Vázquez C). Madrid: Pearson; 2011.
  • Beck AT, Steer RA. Manual. BAI. Inventario de Ansiedad de Beck (Adaptación española: Sanz J.). Madrid: Pearson; 2011.
  • Bjordal K, de Graeff A, Fayers PM, Hammerlid E, van Pottelsberghe C, Curran D, et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 1990 2000; 36: 1796-807. doi: 10.1016/s0959-8049(00)00186-6.
  • Boonzaier A, Schubach K, Troup K, Pollard A, Aranda S, Schofield P. Development of a psychoeducational intervention for men with prostate cancer. J Psychosoc Oncol 2009; 27: 136-53. doi: 10.1080/07347330802616100.
  • Burt J, Caelli K, Moore K, Anderson M. Radical prostatectomy: men’s experiences and postoperative needs. J Clin Nurs 2005; 14: 883-90. doi: 10.1111/j.1365-2702.2005.01123.x.
  • Dąbrowska-Bender M, Słoniewski R, Religioni U, Juszczyk G, Słoniewska A, Staniszewska A. Analysis of quality of life subjective perception by patients treated for prostate cancer with the EORTC QLQ-C30 Questionnaire and QLQ-PR25 module. J Cancer Educ Off J Am Assoc Cancer Educ 2015; 30. doi: 10.1007/s13187-015-0954-5.
  • De Sousa A, Sonavane S, Mehta J. Psychological aspects of prostate cancer: a clinical review. Prostate Cancer Prostatic Dis 2012; 15: 120-7. doi: 10.1038/pcan.2011.66.
  • Dinh KT, Reznor G, Muralidhar V, Mahal BA, Nezolosky MD, Choueiri TK, et al. Association of androgen deprivation therapy with depression in localized prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 2016; 34: 1905-12. doi: 10.1200/JCO.2015.64.1969.
  • Dinh KT, Reznor G, Muralidhar V, Mahal BA, Nezolosky MD, Choueiri TK, et al. Association of androgen deprivation therapy with depression in localized prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 2016; 34: 1905-12. doi: 10.1200/JCO.2015.64.1969.
  • Fayers P, Aaronson N, Bjordal K, Bottomley A, de Graeff A, Groenvold M, et al. EORTC QLQ-C30. Scoring manual. 3ª ed. Brussels: EORTC; 2001. 419 p.
  • Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. J Psychiatr Res 1975; 12: 189-98.
  • Gacci M, Baldi E, Tamburrino L, Detti B, Livi L, De Nunzio C, et al. Quality of life and sexual health in the aging of pca survivors. Int J Endocrinol 2014; 2014: 1-16. doi: 10.1155/2014/470592.
  • Gilbert SM, Sanda MG, Dunn RL, Greenfield TK, Hembroff L, Klein E, et al. Satisfaction with Information used to choose prostate cancer treatment. J Urol 2014; 191: 1265-71. doi: 10.1016/j.juro.2013.12.008.
  • Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst 2009; 101: 888-92. doi: 10.1093/jnci/djp114.
  • Grassi L, Rosti G. Psychosocial morbidity and adjustment to illness among long-term cancer survivors. A six-year follow-up study. Psychosomatics 1996; 37: 523-32. doi: 10.1016/S0033-3182(96)71516-5.
  • Jayadevappa R, Malkowicz SB, Chhatre S, Johnson JC, Gallo JJ. The burden of depression in prostate cancer. Psychooncology 2012; 21: 1338-45. doi: 10.1002/pon.2032.
  • Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer 1948; 1: 634-56. doi: 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L.
  • Lamers RED, Cuypers M, Husson O, de Vries M, Kil PJM, Ruud Bosch JLH, et al. Patients are dissatisfied with information provision: perceived information provision and quality of life in prostate cancer patients. Psychooncology 2016; 25: 633-40. doi: 10.1002/pon.3981.
  • Las cifras del cáncer en España 2019 | Día Mundial del Cáncer 2019 [Internet]. [Acceso 19 de agosto de 2019]. Disponible en: https://seom.org/dmcancer/las-cifras-del-cancer-en-espana-2019/
  • Lintz K, Moynihan C, Steginga S, Norman A, Eeles R, Huddart R, et al. Prostate cancer patients’ support and psychological care needs: Survey from a non-surgical oncology clinic. Psychooncology 2003; 12: 769-83. doi: 10.1002/pon.702.
  • Lobo A, Ezquerra J, Gómez Burgada F, Sala JM, Seva Dïaz A. El Miniexamen cognoscitivo (un test sancillo, práctico para detectar alteraciones intelectualesen pacientes medicos. Rev Psiquiatr Psicol Med 1980; 14: 39-57. doi:
  • Mohler J, Bahnson RR, Boston B, Busby JE, D’Amico A, Eastham JA, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Cancer Netw JNCCN 2010; 8: 162-200. doi:
  • Namiki S, Saito S, Tochigi T, Numata I, Ioritani N, Arai Y. Psychological distress in Japanese men with localized prostate cancer. Int J Urol 2007; 14: 924-9. doi: 10.1111/j.1442-2042.2007.01746.x.
  • National Comprehensive Cancer Network (NCCN). Prostate cancer clinical practice guidelines in oncology, version1 [Internet]. 2014. [Acceso 3 de septiembre de 2019]. Disponible en: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
  • Oraá N, Sánchez M, Lentati G, Mendizabal E, de, Cevas FJ, Martínez N. Eficacia de las intervenciones psicológicas en hombres con cáncer de próstata. Psicooncología 2013; 10: 339-51. doi: 10.5209/rev_PSIC.2013.v10.n2-3.43454.
  • Oraá N. Efecto de variables sociodemgráficas y clínicas en la calidad de vida y los síntomas de ansiedad y depresión en los pacientes con cáncer de próstata. [Madrid]: Universidad Complutense de Madrid; 2017.
  • Prasad SM, Eggener SE, Lipsitz SR, Irwin MR, Ganz PA, Hu JC. Effect of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol 2014; 32(23): 2471-8. doi: 10.1200/JCO.2013.51.1048.
  • Punnen S, Cowan JE, Dunn LB, Shumay DM, Carroll PR, Cooperberg MR. A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU Int 2013; 112: E67-75. doi: 10.1111/bju.12209.
  • Sanz J. Recomendaciones para la utilización de la adaptación española del Inventario de Ansiedad de Beck (BAI) en la práctica clínica. Clin Salud 2014; 25: 39-48. doi: 10.5093/cl2014a3.
  • Sharp L, O’Leary E, Kinnear H, Gavin A, Drummond FJ. Cancer-related symptoms predict psychological wellbeing among prostate cancer survivors: results from the PiCTure study. Psychooncology 2016; 25: 282-91. doi: 10.1002/pon.3909.
  • Sharpley CF, Bitsika V, Christie DRH. “The Worst Thing Was…”: Prostate cancer patients’ evaluations of their diagnosis and treatment experiences. Am J Mens Health 2018; 12: 1503-9. doi: 10.1177/1557988318772752.
  • Sharpley CF, Bitsika V, Christie DRH. The incidence and causes of different subtypes of depression in prostate cancer patients: implications for cancer care. Eur J Cancer Care 2013; 22: 815-23.
  • Steginga SK, Occhipinti S, Dunn J, Gardiner RA, Heathcote P, Yaxley J. The supportive care needs of men with prostate cancer. Psychooncology 2001; 10: 66-75. doi: 10.1002/1099-1611(200101/02)10:1<66::AID-PON493>3.0.CO;2-Z.
  • Van Andel G, Bottomley A, Fosså SD, Efficace F, Coens C, Guerif S, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 1990 2008; 44: 2418-24. doi: 10.1016/j.ejca.2008.07.030.
  • Van der Meulen N, Jansen J, van Dulmen S, Bensing J, van Weert J. Interventions to improve recall of medical information in cancer patients: a systematic review of the literature. Psychooncology 2008; 17: 857-68. doi: 10.1002/pon.1290.
  • Watson E, Shinkins B, Frith E, Neal D, Hamdy F, Walter F, et al. Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up. BJU Int 2016; 117(6B):E10-19. doi: 10.1111/bju.13122.
  • Watts S, Leydon G, Birch B, Prescott P, Lai L, Eardley S, et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open 2014; 4: e003901. doi: 10.1136/bmjopen-2013-003901.
  • Weiss Wiesel TR, Nelson CJ, Tew WP, Hardt M, Mohile SG, Owusu C, et al. The relationship between age, anxiety, and depression in older adults with cancer. Psychooncology 2015; 24: 712-7. doi: 10.1002/pon.3638.
Data source: Dialnet